IL313835A - Bicyclic triazine derivatives for the treatment of cancer - Google Patents

Bicyclic triazine derivatives for the treatment of cancer

Info

Publication number
IL313835A
IL313835A IL313835A IL31383524A IL313835A IL 313835 A IL313835 A IL 313835A IL 313835 A IL313835 A IL 313835A IL 31383524 A IL31383524 A IL 31383524A IL 313835 A IL313835 A IL 313835A
Authority
IL
Israel
Prior art keywords
bicyclic
triazine
history
cancer treatment
cancer
Prior art date
Application number
IL313835A
Other languages
English (en)
Hebrew (he)
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of IL313835A publication Critical patent/IL313835A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL313835A 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer IL313835A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22150829 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL313835A true IL313835A (en) 2024-08-01

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313835A IL313835A (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Country Status (9)

Country Link
US (1) US20250066370A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502240A (cg-RX-API-DMAC7.html)
KR (1) KR20240134962A (cg-RX-API-DMAC7.html)
CN (1) CN118541372A (cg-RX-API-DMAC7.html)
AU (1) AU2023207765A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246440A1 (cg-RX-API-DMAC7.html)
IL (1) IL313835A (cg-RX-API-DMAC7.html)
WO (1) WO2023135057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CA3174507A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
CN118541372A (zh) 2024-08-23
WO2023135057A1 (en) 2023-07-20
CA3246440A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
KR20240134962A (ko) 2024-09-10
AU2023207765A1 (en) 2024-07-04
JP2025502240A (ja) 2025-01-24
US20250066370A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
DK4096717T3 (da) Behandling af cancer
SI3986897T1 (sl) Inhibitor EGFR za zdravljenje raka
ES3065771T3 (en) Substituted oxoisoindoline compounds for the treatment of cancer
DK3956033T3 (da) Bicykliske forbindelser
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
IL314136A (en) Imidazole macrocycles for the treatment of autoimmune disease
IL304595A (en) Bicyclic tetrahydrozepine derivatives for cancer treatment
IL291170A (en) Treatment of hr deficient cancer
EP4493175A4 (en) MIRDAMETINIB TREATMENT
LT4419526T (lt) Heterocikliniai junginiai, skirti vėžiui gydyti
IL281845A (en) Combination therapy for the treatment of cancer
EP4205812C0 (en) FULLY SPHERICAL RADIOTHERAPY SYSTEM
EP4440623A4 (en) Polytherapy for the treatment of cancer
PT3952858T (pt) Método de tratamento de tumores
IL308399A (en) Methods of treating cancer
EP4102649A4 (en) CONNECTOR
EP4090369A4 (en) PERICYTE-SPARKING THERAPY
EP4415766A4 (en) UV RADIATION SOURCE ASSEMBLY
EP4225129A4 (en) OCT GUIDED THERAPY
EP4271392A4 (en) MATRIX-DIRECTED IMMUNOMODULATION FOR CANCER THERAPY
IL289201A (en) Compounds for the treatment of cancer
EP4401721A4 (en) CANCER TREATMENT
EP3952987C0 (en) RADIOTHERAPY OPTIMIZATION SYSTEM
EP4331663A4 (en) LIGHT IRRADIATION SYSTEM
IL305780A (en) Cancer treatment methods